Read by QxMD icon Read

Journal of Clinical Pharmacy and Therapeutics

Miaomiao Yang, Haiping Zhang, Bilin Tao, Hongqiu Pan, Lihuan Lu, Honggang Yi, Shaowen Tang
WHAT IS KNOWN AND OBJECTIVE: Reactive metabolites from anti-tuberculosis (anti-TB) drugs can result in abnormal accumulation of reactive oxygen species (ROS), which plays an important role in anti-TB drug-induced liver injury (ATLI). Liver cells could keep the production of ROS in balance by antioxidant activities. The heme oxygenase 1, encoded by the HMOX1 gene and NADH:quinone oxidoreductase 1, encoded by the NQO1 gene are crucial mediators of cellular defense against ROS. The present study aimed to investigate the associations between HMOX1 and NQO1 polymorphisms and ATLI in Chinese anti-TB treatment population...
February 18, 2019: Journal of Clinical Pharmacy and Therapeutics
Satoshi Kinoshita, Toshihiro Nishizawa, Hideki Mori, Masahiro Kikuchi
No abstract text is available yet for this article.
February 17, 2019: Journal of Clinical Pharmacy and Therapeutics
Tatsuya Suzuki, Takaaki Suzuki, Hirokazu Takatsuka, Shingo Yamazaki, Itsuko Ishii
WHAT IS KNOWN AND OBJECTIVE: Determination of phenobarbital (PB) dosing during continuous haemodiafiltration (CHDF) requires evaluation of both the patient's own clearance and CHDF clearance. CASE DESCRIPTION: Systemic clearance of PB in a 9-year-old female patient with Dravet syndrome, who was undergoing CHDF, was calculated by the Sawchuk-Zaske method, and clearance by CHDF was calculated as the difference between PB levels in influx and efflux, adjusted for the blood purification conditions...
February 15, 2019: Journal of Clinical Pharmacy and Therapeutics
Keliana O'Mara, Sarah Jane Gattoline, Christopher T Campbell
WHAT IS KNOWN AND OBJECTIVE: The International Organization for Standardization (ISO) created enteral device specifications to reduce tubing misconnections. The Global Enteral Device Supplier Association (GEDSA) supports a female design: standard and low dose tip (LDT). Concerns include increased complexity of use with adapters, dosing accuracy and workflow. No peer-reviewed studies have evaluated dosing accuracy of the complete female system with adapters. The objective of this study was to compare dosing accuracy of the female design to legacy syringes...
February 14, 2019: Journal of Clinical Pharmacy and Therapeutics
Volkan Aydin, Ahmet Akici, Fatma Isli, Mesil Aksoy, Mehtap Aydin, Hakki Gursoz
WHAT IS KNOWN AND OBJECTIVE: Anti-tumour necrosis factor-alpha (anti-TNF-α) therapy is known to raise the risk of granulomatous infections, leading to development of risk management strategies at national or global level. This study aimed to determine the relative risk (RR) of tuberculosis (TB) due to anti-TNF-α usage in patients with rheumatologic diseases (RDs) in a nationwide basis. METHOD: This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without anti-TNF-α agents, as registered in the national prescription information system between years 2013 and 2015...
February 14, 2019: Journal of Clinical Pharmacy and Therapeutics
Agnieszka Lisowska, Magdalena Makarewicz-Wujec, Anna M Dworakowska, Małgorzata Kozłowska-Wojciechowska
WHAT IS KNOWN AND OBJECTIVE: Myocardial infarction (MI) in young adults accounts for up to 10% of all cases. Regarding life expectancy and professional activity, it is extremely important to restore and maintain young patients' full performance. Therefore, secondary prevention is especially vital in this group of patients. The paper focuses on the analysis of pharmacotherapy in young MI patients in Poland, assessing disparities between the European Society of Cardiology guidelines and clinical practice, and regional differences among the provinces...
February 14, 2019: Journal of Clinical Pharmacy and Therapeutics
João Pedro Aguiar, Ana Mafalda Brito, Ana Paula Martins, Hubert G M Leufkens, Filipa Alves da Costa
WHAT IS KNOWN AND OBJECTIVE: In the last decades, many lists have been developed to screen for inappropriate prescribing. However, information on which potentially inappropriate medications (PIMs) could increase the cardiovascular risk in the elderly is not objectively presented. This review aimed to identify and quantify those PIMs by extracting information from published PIM-lists. METHODS: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (PRISMA), a systematic review of PIM-lists was conducted...
February 11, 2019: Journal of Clinical Pharmacy and Therapeutics
Gifty M Jojo, Gowthamarajan Kuppusamy
WHAT IS KNOWN AND OBJECTIVE: Alzheimer's disease (AD) is the most common cause of dementia among the elderly. The exact cause of the disease is not clearly known, and no existing therapies are able to prevent disease progression. Identification of the possible "impaired brain insulin signalling in AD" enriched the scope for "the repurposing of diabetic drugs in AD management." Among the different classes of diabetic drugs, pioglitazone (PIO), a PPARγ agonist classed as an insulin sensitizer, is of the highest interest for AD management...
February 9, 2019: Journal of Clinical Pharmacy and Therapeutics
Tao Zhang, Hua Cheng, Yuan Li, Yu-Zhu Dong, Ying Zhang, Xiao-Liang Cheng, An-Min Wang, Ya-Lin Dong
WHAT IS KNOWN AND OBJECTIVE: Increasing reports of the combined use of vancomycin (VAN) and piperacillin/tazobactam leading to higher nephrotoxicity have led to carbapenems being recommended as an alternative option to combine with VAN when nephrotoxicity is a major concern. However, whether carbapenems also increase the nephrotoxicity of VAN is unclear. This study aimed to determine whether meropenem is a suitable drug to combine with VAN based on whether meropenem enhances the nephrotoxicity of VAN...
February 8, 2019: Journal of Clinical Pharmacy and Therapeutics
Manuel Camean-Castillo, Vicente Gimeno-Ballester, Esmeralda Rios-Sanchez, Silvia Fenix-Caballero, Miguel Vázquez-Real, Emilio Alegre-Del Rey
WHAT IS KNOWN AND OBJECTIVE: Rheumatoid arthritis (RA) is an autoimmune disease characterized primarily by inflammation and pain in the joints. Tofacitinib is an oral drug recently approved for RA treatment; it inhibits Janus protein kinases (JAK) that reduces RA symptoms when conventional DMARDs do not trigger a response. This study aimed to compare the efficacy of biological DMARDs in monotherapy or combined with methotrexate in RA patients and compare the treatments. METHODS: We reviewed the literature for articles published up to June 2017, evaluating the efficacy and safety of the biological DMARDs indicated for RA in patients with inadequate responses to conventional DMARDs and naïve to biological DMARDs, in similar populations, considering ACR50 as the efficacy variable...
February 6, 2019: Journal of Clinical Pharmacy and Therapeutics
Syuri Ito-Takeichi, Takashi Niwa, Ayasa Fujibayashi, Keiko Suzuki, Hirotoshi Ohta, Ayumi Niwa, Mayumi Tsuchiya, Masayo Yamamoto, Daijiro Hatakeyama, Akio Suzuki, Hisashi Baba, Nobuo Murakami, Yoshinori Itoh
WHAT IS KNOWN AND OBJECTIVE: Implementation of an antifungal stewardship programme is a recognized need. However, there is insufficient information to confirm the impact of antifungal stewardship interventions. Further, few studies have evaluated the clinical effects of an antifungal stewardship intervention using 1-3, β-D-glucan (βDG) testing. The aim of the present study was to evaluate the impact of implementing an antifungal stewardship with monitoring of βDG values on antifungal use and clinical outcomes...
February 5, 2019: Journal of Clinical Pharmacy and Therapeutics
Manal El-Hamamsy, Iman Fawzy Montasser, Azza El-Sayed Mansy, Dina Ezzeldin Nabet, Mahmoud El-Meteini
WHAT IS KNOWN AND OBJECTIVE: The influence of immunosuppression on the response to antiviral therapy (AVT) for recurrent hepatitis C virus (HCV) infection in liver transplant (LT) recipients remains controversial, especially for the rarely investigated genotype 4. This study aims to compare the effects of the two widely used calcineurin inhibitors (CNIs) (cyclosporine A (CsA) and tacrolimus (Tac)) on the therapeutic response to different AVT regimens. METHODS: A prospective, dual-centre, cohort study of 126 Egyptian living donor liver transplant (LDLT) recipients with recurrent HCV genotype 4 infection, who were categorized into three groups according to the AVT used...
February 3, 2019: Journal of Clinical Pharmacy and Therapeutics
Jones Chun Man Chan, Ming-Him Ng, Raymond Siu Ming Wong, Brian Tomlinson
WHAT IS KNOWN AND OBJECTIVE: SLCO1B1 T521>C variant carriers are susceptible to simvastatin-induced myopathy. We report a patient who developed rhabdomyolysis possibly triggered by a drug-drug and/or herb-drug interaction. CASE DESCRIPTION: A 69-year-old man presented with myalgia and weakness progressing to severe rhabdomyolysis. He had been taking 40 mg simvastatin daily for 10 years and recently consumed supplements, including Stevia rebaudiana and linagliptin...
February 3, 2019: Journal of Clinical Pharmacy and Therapeutics
Jan Schjøtt, Olav Spigset
WHAT IS KNOWN AND OBJECTIVE: Appraisal of drug information centres (DICs) is mainly by word of mouth communication and surveys of overall user satisfaction. Efforts to study the impact of this type of informatics and decision support systematically are generally lacking within the healthcare system. COMMENT: Scandinavian DICs question-answering databases are relevant sources for identifying recurring problems in pharmacotherapy, including drug safety questions, and for re-use of previous answers...
February 1, 2019: Journal of Clinical Pharmacy and Therapeutics
Sabrina Cerqueira-Santos, Kérilin S S Rocha, Thays C Boaventura, Elisdete M S Jesus, Carina C Silvestre, Bárbara M C Sodré- Alves, Divaldo P de Lyra
WHAT IS KNOWN AND OBJECTIVE: Qualified dispensing is fundamental for the promotion of the rational use of medicines. Documentation is an indicator of quality and one of the essential steps in the care process. However, in Brazil, there are no models of clinical documentation applicable to dispensing practices. Thus, the objective of this study was to develop and validate an instrument to document the dispensing process of prescribed medicines. METHODS: A methodological development study was carried out from February 2017 to October 2017 in two stages, which were (i) the development of the instrument and (ii) content validation of the proposed instrument...
January 30, 2019: Journal of Clinical Pharmacy and Therapeutics
Jing Li, Jian Gu
WHAT IS KNOWN AND OBJECTIVE: Clinical trials have demonstrated that the use of ipilimumab has led to considerable improvements in the clinical outcome in patients with advanced melanoma. We conducted a meta-analysis to systematically review the efficacy and safety of ipilimumab for advanced melanoma. STUDY DESIGN: The relevant randomized controlled trials in melanoma patients treated with ipilimumab were retrieved, and the systematic evaluation was conducted. EMBASE, MEDLINE and PubMed were searched for articles published till May 2018...
January 28, 2019: Journal of Clinical Pharmacy and Therapeutics
Frédéric Bloch, Ilhem Karoui, Samir Boutalha, Christian Defouilloy, Jean-Marc Dubaele
WHAT IS KNOWN AND OBJECTIVE: Behavioural disorders are difficult to manage in elderly demented patients because of the lack of appropriate drugs or difficulties surrounding the route of administration. The tolerability of Midazolam is well described in the emergency management of agitation for young patients, when administered intramuscularly or intravenously. However, very little data are available on the use of oral Midazolam for this indication and in the elderly population. METHODS: A literature review was conducted, and studies were included if involving adults, receiving Midazolam, alone or in combination, whatever the route, dosage or indication and if they reported adverse events related to the use of Midazolam...
January 21, 2019: Journal of Clinical Pharmacy and Therapeutics
Karen P H Mattos, Isabela R Gouvêa, Júlia C F Quintanilha, Maria A Cursino, Pedro E N S Vasconcelos, Patricia Moriel
WHAT IS KNOWN AND OBJECTIVE: Polymyxins, especially polymyxin B, has become the last line of therapy against Gram-negative pathogens' carbapenemase producers. However, given increasing use of polymyxin B in clinical settings its therapeutic value has been evaluated worldwide due to its toxic effects. The aim of this study was to assess the efficacy and safety of antimicrobial therapy with polymyxin B in patients with multidrug-resistant bacteria in Brazil. METHODS: This was a prospective cohort study in a 403-bed academic tertiary care centre, located in the countryside of Brazil...
January 21, 2019: Journal of Clinical Pharmacy and Therapeutics
Birgit Ehlken, Massoud Toussi, Abdus Samad, Sigal Kaplan, Mónika Domahidy, Hanka de Voogd, Stella Böhmert, Rita Silveira Ramos, Deepa Arora
WHAT IS KNOWN AND OBJECTIVE: The approved indication for trimetazidine (TMZ) was restricted to "add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies" in 2012 by the Committee for Medicinal Products for Human Use (CHMP). TMZ was no longer indicated for ophthalmology and otolaryngology (ENT) indications. This drug utilization study analysed actual utilization of TMZ before and after the restriction on its indications to evaluate the effectiveness of risk minimization measures (RMM)...
January 18, 2019: Journal of Clinical Pharmacy and Therapeutics
Hien Nguyen, Angel Pan, Craig Smollin, Lee F Cantrell, Tom Kearney
WHAT IS KNOWN: Cyproheptadine is a serotonin and histamine antagonist that has been suggested as a treatment for serotonin syndrome in case reports. OBJECTIVE: We sought to examine the differences between outcomes and treatment recommendations in patients who received and did not receive cyproheptadine for a probable serotonin syndrome. METHODS: A retrospective review of cases reported to the California Poison Control System between 2006 and 2017 involving cyproheptadine administration or consideration for treatment of a probable serotonin syndrome...
January 16, 2019: Journal of Clinical Pharmacy and Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"